GFAP and Huntington disease: In another model of Huntington's disease VCE‐003.2 (10 mg·kg−1 i.p.)prevented neuronal loss, indicated by increases in Nissl and NeuN staining and at the same dose improved RotaRod performance and reduced astrogliosis in mice, measured by attenuated levels of GFAP and ionized calcium binding adaptor molecule 1 (Iba‐1; Díaz‐Alonso et al., 2016).